Swiss vs German Biotech Manufacturing 2026: A Practical Comparison

Switzerland’s biotech manufacturing brand is built around Lonza. The Visp site anchors large-scale biologics and antibody-drug conjugate capacity in a way that is still hard to match elsewhere in Europe. Around Lonza, the rest of the Swiss picture specialises: Bachem (Bubendorf) on peptides and oligonucleotide-peptide conjugates, Octapharma (Lachen) on plasma derivatives, Sandoz (Basel) on biosimilars and generics at scale, Siegfried (Zofingen) on API and small-molecule CDMO, and Ypsomed (Burgdorf) on drug-delivery devices. Pharma anchors (Roche, Novartis) sit behind these as demand drivers. The net effect is a small but deep manufacturing base where each company is a category leader.

Germany’s manufacturing case is different: more operators, more regional distribution, more specialisation breadth. Rentschler Biopharma (Laupheim) is the closest German parallel to Lonza for mid-cap biologics, with a published regulatory track record. Vetter Pharma (Ravensburg) holds a top-tier position in sterile fill-finish for biologics. IDT Biologika (Dessau-Rosslau) adds viral-vector and vaccine capacity — including COVID-era large-scale vaccine manufacturing. Wacker Biotech (Halle/Jena) specialises in microbial fermentation. ProBioGen (Berlin) adds cell-line development and high-yield CHO services. Merck KGaA (Darmstadt) and Gerresheimer (Düsseldorf) sit behind this layer as pharma and pharma-packaging anchors.

A practical decision rule: programmes that need large-integrated biologics capacity in one site, plus the Lonza brand signal for partners and investors, land in Switzerland. Programmes that need mid-cap clinical-to-commercial biologics, sterile fill-finish alongside drug substance, or specialised services (vaccines, viral vectors, microbial fermentation) find more optionality in Germany. Programmes that need peptides or oligo-peptide conjugates go to Bachem in Switzerland almost regardless of other criteria. Programmes that need geographic redundancy across multiple sites should probably use Germany as the primary country simply because there are more operators to choose from.

Capacity and pricing in 2026 are not in the published record in any way that is meaningful for a sponsor. Both Switzerland and Germany are under meaningful demand pressure in biologics, ADC, and sterile fill-finish. What sponsors can verify: published inspection history (EMA, FDA), known regulatory findings, public statements on capacity expansion (Lonza Visp expansions, Rentschler and Vetter expansions have all been disclosed publicly), and the depth of the mid-cap CDMO alternative layer — which is where a second-source strategy usually lands.

Switzerland is not in the EU but is deeply integrated operationally — it participates in the single market for most purposes and uses GDP-aligned pharmaceutical logistics through the same operators (DHL Life Sciences & Healthcare, World Courier, Kuehne+Nagel Healthcare) that cover Germany. Cross-border movement between Swiss manufacturing and German partners, or from Swiss sites to Polish and Baltic nodes, runs on commercial GDP rails. For a sponsor planning a manufacturing footprint, Switzerland is not a friction layer — but FDA/EMA cross-regulatory planning, tariff codes, and release testing should be mapped early.